First no-prescription birth control pill approved in US

First no-prescription birth control pill approved in US

Advocates called the approval of the birth control pill without a perscription a 'victory for equity'
Advocates called the approval of the birth control pill without a perscription a 'victory for equity'. Photo: Handout / Perrigo Company/AFP
Source: AFP

US health authorities on Thursday approved the first over-the-counter birth control pill in the country, dramatically widening access to contraception for women in the United States where abortion rights are increasingly under assault.

The medication, Opill, will become available in pharmacies and supermarkets as well as online early next year, the manufacturer Perrigo said in a statement.

More than 100 countries already allow contraceptive pills to be sold over the counter. But in the United States approval comes after the Supreme Court last year scrapped federal abortion protections and the procedure is now banned in several states.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the Food and Drug Administration's Center for Drug Evaluation and Research in a statement.

Read also

Doctors walk out in UK health service's biggest strike

"When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy."

The agency warned, however, that the pill should not be taken by women who have or have ever had breast cancer.

PAY ATTENTION: Click “See First” under the “Following” tab to see Briefly News on your News Feed!

'Victory for equity'

Almost half of the 6.1 million pregnancies in the United States each year are unintended, according to the FDA.

Allowing women to access the progestin-only daily contraceptive pill without needing to see a doctor first "may help reduce the number of unintended pregnancies and their potential negative impacts," the FDA statement said.

Activists campaign for acces to birth control in Washington in June 2023
Activists campaign for acces to birth control in Washington in June 2023. Photo: SAUL LOEB / AFP/File
Source: AFP

The pill, produced by the pharmaceutical company HRA Pharma, which was recently acquired by Perrigo, had already been authorized for prescription in the United States for a number of years.

Read also

Why American communities are suing Big Oil for climate damages

"This moment is a victory for equity, human rights, public health, and evidence-based research—and especially in light of the ongoing attacks on reproductive health and rights, it is a reason to celebrate," said the Free the Pill coalition, a leading advocacy group.

Experts say the decision could be especially significant for teenage girls who may find it harder to get to the doctor, particularly if they want to do it on their own.

"An over-the-counter birth control pill has the potential to transform the way people access contraception, especially those who face the most barriers in our health care system, including LGBTQIA+ folks, people of color, and those working to make ends meet," said Lin-Fan Wang, a family physician serving the LGBTQ community and a Free the Pill member.

In May, an expert advisory committee convened by the FDA unanimously voted in favor of authorizing the sale of Perrigo without a prescription, judging that the benefits outweighed the risks.

Read also

'Meta loses more': Zuckerberg takes Threads fight to EU

The contraceptive pill, taken daily at the same time, prevents a pregnancy during sexual intercourse.

PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ click on “Recommended for you” and enjoy!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.